| P2093 | author name string | Fei Wang | |
| | Juan Wang | |
| | Qingwen Zhang | |
| | Qidong You | |
| | Xiuhua Chen | |
| | Houyuan Zhou | |
| | Yunsong He | |
| P2860 | cites work | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 |
| | Guilty as charged: B-RAF is a human oncogene | Q28288202 |
| | Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors | Q28297412 |
| | Patterns of somatic mutation in human cancer genomes | Q29547841 |
| | Rational design of inhibitors that bind to inactive kinase conformations | Q29617558 |
| | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 |
| | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 |
| | Chemical inhibitors of protein kinases | Q34466054 |
| | Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors | Q36723753 |
| | Small molecule inhibitors of BRAF in clinical trials | Q37973551 |
| | Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. | Q39779613 |
| | Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). | Q39867959 |
| | Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases | Q40500728 |
| | Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity | Q42775676 |
| | The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. | Q42973748 |
| P433 | issue | 1 | |
| P304 | page(s) | 27-36 | |
| P577 | publication date | 2013-10-25 | |
| P1433 | published in | Chemical Biology and Drug Design | Q15749458 |
| P1476 | title | Identification of type II inhibitors targeting BRAF using privileged pharmacophores | |
| P478 | volume | 83 | |